← Back to Treatments
🏅 FDA Orphan Designation

Yondelis

trabectedin

Manufacturer: Janssen Research & Development, LLC

Indicated for:
Alveolar soft tissue sarcomaOrphanPleomorphic liposarcoma

FDA-Approved Indications (2)

For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen

indicated for the treatment of adult patients with unresectable or metastatic liposarcoma who received a prior anthracycline-containing regimen

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE YONDELIS ® is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . YONDELIS is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )

💙 Support Programs

View all →
YONDELIS
Janssen
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.